Stability of an extemporaneously prepared recombinant human interferon alfa-2b eye drop formulation.

PURPOSE The stability of an extemporaneously prepared recombinant human interferon alfa-2b (rh-IFN-alpha2b) eye drop formulation was studied. METHODS A volume of 3 x 10(6) International Units (IU) of rh-IFN-alpha2b formulated in solution was diluted with 5 mL of a 0.01% benzalkonium chloride solution. The stability of the extemporaneous formulation was evaluated for 30 days at room temperature (5 +/- 3 degrees C) and at 28 +/- 2 degrees C. Solutions were periodically subjected to bioactivity assay (antiviral titration), enzyme-linked immunosorbent assay, preservative-efficacy and sterility testing, organoleptic evaluation, and pH testing. Preservative efficacy was tested against five microorganisms. The organoleptic characteristics were verified by checking for the transparency and absence of suspended solids against light and dark backgrounds. Statistical significance was determined using analysis of variance after a comparison of the homogeneity of variance (Bartlett's test). RESULTS Results from this evaluation indicated that the formulation was stable for 15 days at 5 +/- 3 C. During this storage period, the biological activity varied between 80 and 125% of the nominal value (0.5 x 10(6) IU/mL). The formulation was sterile and organoleptically acceptable. The pH ranged from 6.7 to 7.3, and the preservative was effective. The formulation was stable for 7 days when stored at 28 +/- 2 degrees C. The formulation remained sterile, colorless, and without suspended solids. The pH range was 6.7-7.3. CONCLUSION An extemporaneously pre -pared rh-IFN-alpha2b eye drop formulation was stable at 5 +/- 3 degrees C for 15 days and at 28 +/- 2 degrees C for 7 days.

[1]  J. Herson,et al.  Topical human fibroblast interferon for acute adenoviral conjunctivitis , 1987, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  L. Ruiz,et al.  Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin. , 2003, International journal of pharmaceutics.

[3]  S. Clarke,et al.  Pemetrexed: single-agent and combination phase I study overview. , 2002, Seminars in oncology.

[4]  M. Britton The epidemiology of mesothelioma. , 2002, Seminars in oncology.

[5]  C. Karp,et al.  Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon α-2b , 2001 .

[6]  W Wang,et al.  Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.

[7]  P. Cony-Makhoul,et al.  Response at Three Months Is a Good Predictive Factor for Newly Diagnosed Chronic Myeloid Leukemia Patients Treated by Recombinant Interferon-Presented in part at the 38th annual meeting of the American Society of Hematology, Orlando, FL, December 6-10, 1996. , 1998 .

[8]  P. Cony-Makhoul,et al.  Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. , 1998, Blood.

[9]  M. Tomita,et al.  Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. , 1996, Journal of pharmaceutical sciences.

[10]  N. Maria,et al.  The use of deferoxamine infusions to enhance the response rate to interferon‐α treatment of chronic viral hepatitis B , 1996, Journal of viral hepatitis.

[11]  T. C. Barnett,et al.  Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study. , 1996, Cancer biotherapy & radiopharmaceuticals.

[12]  J. Pepose,et al.  Topical interferon alpha-2a treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient. , 1995, Cornea.

[13]  A. Deplano,et al.  Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. , 2008, Liver.

[14]  L. Reynolds Guidelines for the preparation of sterile ophthalmic products. , 1991, American journal of hospital pharmacy.

[15]  M. Yin-Murphy,et al.  Inhibition of epidemic isolates of coxsackievirus type A 24 by recombinant and natural interferon alpha and interferon beta. , 1988, Intervirology.

[16]  A. Romano,et al.  Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections. , 1988, Metabolic, pediatric, and systemic ophthalmology.

[17]  M. Hoffman Acute haemorrhagic conjunctivitis. , 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.